Table 1.
Patient and treatment characteristics1
| Characteristic | N = 20 |
|---|---|
| Sex | |
| Female | 7 (35%) |
| Male | 13 (65%) |
| Median Age at Diagnosis, y | 60 (48, 64) |
| Race | |
| Asian | 1 (5.0%) |
| Black | 1 (5.0%) |
| White | 18 (90%) |
| Karnofsky Performance Status | |
| 70–80 | 8 (40.0%) |
| 90–100 | 12 (60%) |
| Recursive Partitioning Analysis Class | |
| III | 5 (25%) |
| IV | 15 (75%) |
| Resection Extent | |
| Gross total resection | 7 (35%) |
| Subtotal resection | 12 (60%) |
| Biopsy only | 1 (5.0%) |
| IDH 1/2 Status | |
| Wildtype | 19 (95%) |
| Mutated | 1 (5.0%) |
| MGMT Methylation | |
| No | 17 (75%) |
| Yes | 3 (15%) |
| Tumor Maximum Dimension, cm | 4.35 (3.95, 5.05) |
| Maintenance Temozolomide, cycles | 6 (1,14)2 |
| Use of TTF | |
| No | 15 (75%) |
| Yes | 5 (25%) |
| Time from Surgery to RT | 4.21 (3.36, 4.46) |
1Statistics presented: n (%); median (IQR).
2Median (range).